Publication | Open Access

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

InflammationChronic Inflammatory DiseasesAnti-inflammatoryAutoimmune DiseaseCrohn ’ImmunologyGastroenterologyImmune-mediated Inflammatory DiseasesMedicineInflammatory DiseaseDisease Refractory